19 October 2014- GSK says Ebola vaccine development progressing at 'unprecedented rate'
GlaxoSmithKline is working to develop a vaccine to combat Ebola, which has killed thousands in West Africa, was moving at a rapid pace.
"Development of the vaccine candidate is progressing at an unprecedented rate, with first phase 1 safety trials with the vaccine candidate underway in the USA, UK and Mali, and further trials due to start in the coming weeks," the firm said in a statement posted on its website.
Source : REUTERS
GSK on London Stock exhange : GSK
No comments:
Post a Comment